British Patient Capital announces its participation in Quantexa’s series C funding round as Quantexa announces the close of the round at $64.7 million (£51.2m).The deal is the first direct investment by British Patient Capital in a company as part of a long-term co-investment strategy that identifies and supports high-potential, later-stage UK companies in its underlying portfolio. In the case of Quantexa, British Patient Capital had a prior exposure via its commitment to Dawn Capital’s third fund.